Måndag 22 Juni | 20:53:58 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 12:00 Kvartalsrapport 2026-Q3
2026-08-05 12:00 Kvartalsrapport 2026-Q2
2026-05-31 - Kvartalsrapport 2026-Q1
2026-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2026-05-26 - Extra Bolagsstämma 2026
2026-05-26 - Årsstämma
2026-03-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Koncernen omfattar tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-22 16:24:00

On 2 June 2026, Magle Chemoswed Holding AB (publ) (the "Company") announced that it had initiated a written procedure in relation to its senior secured bonds 2025/2028 with ISIN SE0025197403 (the "Bonds"), to request the holders of the Bonds to vote in favour of, among other things, (i) amending and waiving certain provisions of the terms and conditions of the Bonds so as to make the financial indebtedness and security incurred and granted in connection with the bridge loan facility agreement dated 27 May 2026 (the "Bridge Loan Agreement") permitted thereunder, and (ii) offering all holders of the Bonds the opportunity to participate in the Bridge Loan Agreement on a pro rata basis in proportion to their respective shares of the adjusted nominal amount (the “Written Procedure”). The Lenders under the Bridge Loan Agreement will, as consideration for the financing provided thereunder, receive additional bonds (the "Bonus Bonds") issued by the Company. The full details of the proposals are set out in the notice of the Written Procedure.

A sufficient number of holders of Bonds participated in the Written Procedure and the requisite majority voted in favour of the proposals. The Company is therefore pleased to announce the successful completion of the Written Procedure.

The Company will continue with the implementation of the contemplated amendments and waivers as set out in the notice of Written Procedure and will proceed with the issuance of the Bonus Bonds. Any Bondholder who, in accordance with the instructions set out in the notice of the Written Procedure, has subscribed to participate in the facility under the Bridge Loan Agreement will be contacted directly.